XTALPI, a global leader in AI and robotic automation for R&D, announced the successful delivery and acceptance of an automated drug discovery and process optimization laboratory for JW Pharmaceutical in South Korea.

• Milestone Transaction: This project, valued at over 10 million RMB, marks the first large-scale overseas deployment of XTALPI’s AI-autonomous experimental platform within an international pharmaceutical facility.
• Solving R&D Bottlenecks: Traditional trial-and-error manual experiments suffer from human error and throughput limits. The new platform integrates high-throughput automated synthesis, AI reaction optimization, and Bayesian Optimization algorithms.
• Performance Gains: The system is capable of 24/7 unmanned operation, improving labor efficiency by 5x and data collection capacity by 40x. This "High-Throughput Experiment → High-Quality Data → High-Precision Model" closed-loop mechanism allows JW to accelerate the identification of drug candidates with high developability.
• Modular Versatility: XTALPI’s "Lego-style" modular design consists of over 30 flexible modules, allowing the platform to be adapted not only for drug discovery but also for cosmetics, new energy materials, and chemical engineering, effectively breaking down "data silos" in industrial R&D.

Resource: 晶泰科技拿下韓國 JW 千萬級人民幣戰略合作 AI 機器人實驗室海外落地